Takeda Pharma Files 6-K, Confirms 20-F Reporting
Ticker: TKPHF · Form: 6-K · Filed: Jul 30, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jul 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, reporting-status
TL;DR
Takeda filed a 6-K on 7/30/25 confirming it's a foreign private issuer using Form 20-F for annual reports.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on July 30, 2025, reporting its status as a foreign private issuer. The filing indicates that Takeda will file its annual reports under Form 20-F. The company is headquartered in Tokyo, Japan.
Why It Matters
This filing confirms Takeda's reporting structure with the SEC, which is important for investors tracking its financial disclosures.
Risk Assessment
Risk Level: low — This is a routine administrative filing confirming reporting status and not disclosing new material financial or operational information.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer of the 6-K report
- Form 6-K (document) — Type of SEC filing
- Form 20-F (document) — Annual report form for foreign private issuers
- July 30, 2025 (date) — Date of the filing and reporting period
FAQ
What is the purpose of this Form 6-K filing by Takeda Pharmaceutical Company Limited?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to provide information to the SEC.
Which form will Takeda use for its annual reports?
Takeda indicates it will file its annual reports under cover of Form 20-F.
What is Takeda's principal executive office address?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
What is Takeda's SEC file number?
Takeda's SEC file number is 001-38757.
Is Takeda submitting this Form 6-K in paper format?
The filing includes checkboxes for submitting in paper as permitted by Regulation S-T Rule 101(b)(1) and Rule 101(b)(7), but it is not indicated whether Takeda is utilizing these options.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 30, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).